The First Autonomous Blood Draw Robot That Replaces the Human Needle
Vitestro's Aletta is the first autonomous blood draw robot that locates veins, inserts the needle, collects samples, and applies the bandage with a 94.5% first-stick success rate.
Photo source:
Aletta
94.5% First-Stick Success, Zero Serious Adverse Events, and No Human Hands on the Needle
Those
numbers come from a peer-reviewed multicenter clinical trial published in
Clinical Chemistry, one of the most respected journals in laboratory medicine.
They describe the performance of a machine that does something no device has
done before: draw blood from a patient's arm entirely on its own. Not assisted
by a nurse. Not supervised step by step. The patient sits down, places their
arm, presses a button, and the robot does the rest, from finding the vein to
applying the bandage.
Vitestro,
a medical robotics company headquartered in Utrecht, Netherlands, built Aletta
as the world's first autonomous blood draw robot. The device carries the CE
Mark for clinical use in the European Union and has been validated in over
4,000 patients. Co-founder and Commercial Director Brian Joseph named it after
Dr. Aletta Jacobs, the first female physician in the Netherlands, whose work
reshaped access to healthcare in the country. Vitestro raised $70 million in an
oversubscribed Series B round backed by Labcorp Venture Fund, Mayo Clinic, and
Sutter Health, alongside financial investors including InterVest, PGGM, Puma
Venture Capital, and continued support from Invest-NL, the European Innovation
Council Fund, and robotics pioneer Fred Moll.
How This Autonomous Blood Draw Robot Finds the Vein
The
central technical challenge in automated phlebotomy is locating the right vein
reliably. Human phlebotomists use touch, visual cues, and experience to find a
suitable site. Aletta replaces that process with multimodal imaging that
combines near-infrared light and ultrasound to map the vasculature beneath the
skin. Once a candidate vein is identified, the system uses Doppler ultrasound
to confirm blood flow direction and verify that the target is a vein and not an
artery. This three-layer confirmation process runs before the needle is ever
positioned.
After
confirming the vein, Aletta positions and inserts the needle with submillimeter
precision using a robotic arm. The system then manages the rest of the
collection process autonomously. It changes blood collection tubes as needed,
inverts them to ensure proper mixing with additives, and applies a bandage
after the needle is withdrawn. The entire sequence, from tourniquet to bandage,
executes without a human touching the patient. This level of end-to-end
automation is what distinguishes Aletta from earlier vein-finding devices or
needle-guidance systems that still require a human operator to perform the
actual draw.
Exploring the Clinical Evidence Behind This Autonomous Blood Draw Robot
The
EU ADOPT trial, a multicenter study conducted across four Dutch hospitals,
generated the clinical data that supported Aletta's CE Mark certification.
Results published in Clinical Chemistry showed a first-stick success rate of
94.5%. Among patients who completed the process, 90% reported that the pain was
less than or similar to a manual blood draw performed by a human phlebotomist.
When asked about future preference, 82% said they would choose Aletta or had no
preference between the robot and a human.
The
safety profile was equally notable. Mild adverse events occurred in only 0.6%
of procedures. No moderate or serious adverse events were recorded during the
trial. The four clinical partner sites, OLVG Lab in Amsterdam, St. Antonius
Hospital in Utrecht, Result Laboratorium in Dordrecht, and Amsterdam UMC,
continue to use Aletta in clinical and pre-commercial settings. These hospitals
represent a range of laboratory volumes and patient populations, providing
diversity in the operational data that informs ongoing refinements to the
system.
How Aletta Changes the Staffing Equation for Blood Draw Centers
Phlebotomy
departments worldwide face a persistent staffing shortage. Trained
phlebotomists are difficult to recruit, expensive to train, and prone to
turnover. When a blood draw center is short-staffed, wait times increase,
patient throughput drops, and the remaining staff face heavier workloads that
increase the risk of errors. Aletta is designed to change that equation
directly. In Vitestro's operational model, one trained supervisor can oversee
up to three Aletta devices simultaneously. This means a single staff member can
manage the output of what would traditionally require three separate
phlebotomists.
Beyond
staffing, the autonomous blood draw robot addresses preanalytical variability,
one of the largest sources of error in diagnostic laboratory workflows. When
blood is collected manually, technique varies between practitioners.
Differences in tourniquet pressure, needle angle, tube handling, and mixing can
all affect sample quality. By standardizing every step of the collection
process through robotic execution, Aletta reduces the human-dependent
variability that contributes to preanalytical errors. Vitestro positions this
consistency as a step toward fully automated laboratory workflows where the
collection, transport, and analysis of blood samples are all handled by
machines.
Where Autonomous Phlebotomy Fits in the Future of Diagnostics
Aletta
is currently CE-marked and deployed in clinical settings across the European
Union. It is not yet approved by the FDA and is not available for use in the
United States. Vitestro is actively pursuing the FDA De Novo regulatory
pathway, with proceeds from the Series B round earmarked for that process
alongside manufacturing scale-up and commercial infrastructure development.
Clinical research collaborations are underway with Mayo Clinic Rochester,
Baylor Scott and White Research Institute, and Northwestern Medicine. Market
research collaborations are in progress with Advocate Health, BayCare,
Intermountain Health, and the Medical University of South Carolina.
The
broader question facing autonomous phlebotomy is whether patients and
healthcare systems will trust a robot with a procedure that has been performed
by human hands for over a century. The clinical data from the ADOPT trial
provides an initial answer: the majority of patients found the experience
comparable to or better than a manual draw, and the safety record was strong.
Whether that acceptance holds across larger and more diverse patient
populations, and whether hospital administrators see the operational and
financial case for deployment, will determine how quickly the autonomous blood
draw robot moves from early adoption at Dutch hospitals to standard practice in
blood draw centers worldwide.
You have exceeded your free limits for viewing our premium content
Please subscribe to have unlimited access to our innovations.
Get The Latest In Innovation
Join Our Newsletter
Where bold ideas find bold readers.
